Friday, March 05, 2021 6:08:47 AM
https://www.investopedia.com/terms/p/poisonpill.asp#:~:text=A%20poison%20pill%20is%20a,of%20a%20new%2C%20hostile%20party.
Poison Pill
By ADAM HAYES
Reviewed By AMY DRURY
Updated Sep 22, 2020
What Is a Poison Pill?
The term poison pill refers to a defense strategy used by a target firm to prevent or discourage a potential hostile takeover by an acquiring company. Potential targets use this tactic in order to make them look less attractive to the potential acquirer. Although they're not always the first—and best—way to defend a company, poison pills are generally very effective.
A poison pill is a defense tactic utilized by a target company to prevent or discourage hostile takeover attempts.
Poison pills allow existing shareholders the right to purchase additional shares at a discount, effectively diluting the ownership interest of a new, hostile party.
Poison pills often come in two forms—the flip-in and flip-over strategies.
How Poison Pills Work
Takeovers are fairly common in the business world, where one company makes an offer to assume control over another. Larger companies tend to take over smaller ones if they want to get into a new market, when there are operational benefits by combining both entities, or when the acquirer wants to eliminate the competition. Takeovers, though, aren't always harmonious and become hostile when the target doesn't entertain or want to be taken over.
When a company becomes the target of a hostile takeover, it may use the poison pill strategy to make itself less attractive to the potential acquirer. As the name indicates, a poison pill is analogous to something that's difficult to swallow or accept. A company targeted for an unwanted takeover may use a poison pill to make its shares unfavorable to the acquiring firm or individual.
Poison pills also significantly raise the cost of acquisitions and create big disincentives to deter such attempts completely.
You said ...
Recent HMBL News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 02:19:41 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 01/03/2024 05:00:32 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/06/2023 09:05:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2023 01:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 09:20:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/31/2023 01:15:12 PM
- Form 1-A - Offering Statement [Regulation A] • Edgar (US Regulatory) • 08/22/2023 07:48:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:14:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:53:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:15:09 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 06/30/2023 08:35:16 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM